We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
3 result(s) found, displaying 1 to 3
-
Australian public assessment report (AusPar)Kalydeco (ivacaftor) was approved to treat cystic fibrosis in patients aged 4 months and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Elexacaftor/tezacaftor/ivacaftor and ivacaftor
-